Organization Overview
Alternative names
acalabrutinib (calquence) (2 trials)
allogeneic stem cells (1 trial)
anidulafungin (eraxis) (1 trial)
autologous bone marrow derived mesenchymal cells (1 trial)
autologous hematopoietic stem cells (1 trial)
cyclophosphamide (cytoxan) (9 trials)
daratumumab (darzalex) (1 trial)
daunorubicin (cerubidine) (1 trial)
doxorubicin (Doxil) (3 trials)
fludarabine (fludara) (2 trials)
Infections (Phase 3)
Leukemia (Phase 4)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)
Leukemia, Lymphoid (Phase 3)
Leukemia, Myeloid (Phase 3)
Leukemia, Myeloid, Acute (Phase 3)
Leukemia, Promyelocytic, Acute (Phase 4)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 2)
Lymphoma, Follicular (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Mantle-Cell (Phase 3)
Lymphoma, Non-Hodgkin (Phase 3)
Multiple Myeloma (Phase 3)
Myelodysplastic Syndromes (Phase 3)
Neoplasms, Plasma Cell (Phase 3)
Preleukemia (Phase 3)
Primary Myelofibrosis (Phase 2)
Smoldering Multiple Myeloma (Phase 2)
Syndrome (Phase 3)